Octagam Immune Globulin (Human)
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Octagam Immune Globulin (Human)
- Generic name
- IMMUNE GLOBULIN
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- eb4c342b-122c-0072-1428-1747882e6c00
- SPL ID
- 86003c7c-517c-9c41-8960-cace21be471c
- Version
- 2
- Effective date
- 2024-01-26
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:32
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125062 | derived:openfda.application_number |
| application number | BLA125062 | openfda.application_number | |
| brand name | Octagam Immune Globulin (Human) | openfda.brand_name | |
| generic name | IMMUNE GLOBULIN | openfda.generic_name | |
| manufacturer name | Pfizer Laboratories Div Pfizer Inc | openfda.manufacturer_name | |
| ndc | package | 0069-6111-01 | openfda.package_ndc |
| ndc | package | 0069-6550-02 | openfda.package_ndc |
| ndc | package | 0069-6550-01 | openfda.package_ndc |
| ndc | package | 0069-6002-02 | openfda.package_ndc |
| ndc | package | 0069-6002-01 | openfda.package_ndc |
| ndc | package | 0069-6339-02 | openfda.package_ndc |
| ndc | package | 0069-6339-01 | openfda.package_ndc |
| ndc | package | 0069-6111-02 | openfda.package_ndc |
| ndc | package | 0069-6237-01 | openfda.package_ndc |
| ndc | package | 0069-6237-02 | openfda.package_ndc |
| ndc | product | 0069-6339 | openfda.product_ndc |
| ndc | product | 0069-6550 | openfda.product_ndc |
| ndc | product | 0069-6002 | openfda.product_ndc |
| ndc | product | 0069-6237 | openfda.product_ndc |
| ndc | product | 0069-6111 | openfda.product_ndc |
| ndc11 | package | 00069655002 | derived:openfda.package_ndc |
| ndc11 | package | 00069623702 | derived:openfda.package_ndc |
| ndc11 | package | 00069655001 | derived:openfda.package_ndc |
| ndc11 | package | 00069611101 | derived:openfda.package_ndc |
| ndc11 | package | 00069600201 | derived:openfda.package_ndc |
| ndc11 | package | 00069611102 | derived:openfda.package_ndc |
| ndc11 | package | 00069633902 | derived:openfda.package_ndc |
| ndc11 | package | 00069623701 | derived:openfda.package_ndc |
| ndc11 | package | 00069600202 | derived:openfda.package_ndc |
| ndc11 | package | 00069633901 | derived:openfda.package_ndc |
| rxcui | 1809503 | openfda.rxcui | |
| rxcui | 2170634 | openfda.rxcui | |
| rxcui | 1809444 | openfda.rxcui | |
| rxcui | 1809499 | openfda.rxcui | |
| rxcui | 1809502 | openfda.rxcui | |
| rxcui | 1809501 | openfda.rxcui | |
| rxcui | 1809421 | openfda.rxcui | |
| rxcui | 1809497 | openfda.rxcui | |
| rxcui | 1809414 | openfda.rxcui | |
| rxcui | 1809539 | openfda.rxcui |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. (See WARNING and PRECAUTIONS [ 5.5 ], PATIENT COUNSELING INFORMATION [ 17 ] Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including Octagam 10%. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV product containing sucrose. Octagam 10% does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or acute renal failure, administer Octagam 10% at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. (See DOSAGE and ADMINISTRATION [ 2.3 ], WARNINGS and PRECAUTIONS [ 5.5 ]) WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE See full prescribing information for complete boxed warning Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of Immune Globulin Intravenous (Human) (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam 10% does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam 10% at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions to Octagam 10%. Epinephrine should be available immediately to treat any severe acute hypersensitivity reactions ( 5.1 ). Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure ( 5.2 ). Falsely elevated blood glucose readings may occur during and after the infusion of Octagam 10% with testing by some glucometers and test strip systems ( 5.3 ). Hyperproteinemia, increased serum osmolarity and hyponatremia may occur in patients receiving Octagam 10% ( 5.4 ). Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to Octagam 10% treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia ( 5.6 ). Aseptic Meningitis Syndrome may occur in patients receiving Octagam 10%, especially with high doses or rapid infusion ( 5.7 ). Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury (TRALI)) ( 5.8 ). Octagam 10% is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent ( 5.9 ). 5.1 Hypersensitivity Severe hypersensitivity reactions may occur (See Contraindications ( 4 ) ) .[ 1 ] In case of hypersensitivity, discontinue Octagam 10% infusion immediately and institute appropriate treatment. Epinephrine should be immediately available for treatment of severe acute hypersensitivity reactions. Octagam 10% contains trace amounts of IgA (average 106 µg/mL in a 10% solution). IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactoid reactions when administered Octagam 10% (See Contraindications ( 4 )) . Octagam 10% may cause hypersensitivity reactions in patients with corn allergy. Octagam 10% contains maltose, a disaccharide sugar which is derived from corn. 5.2 Renal Dysfunction/Failure Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur upon use of Octagam 10% in predisposed patients. Ensure that patients are not volume depleted prior to the initiation of the infusion of Octagam 10%. For patients at risk of renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure (such as individuals with diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or those receiving known nephrotoxic drugs), administer Octagam 10% at the minimum infusion rate practicable, not to exceed 3.3mg/kg/min (0.03mL/kg/min) (See Boxed Warning, and Dosage and Administration ( 2 )). Periodic monitoring of renal function tests and urine output is particularly important in patients judged to be at risk of developing acute renal failure. Assess renal function, including a measurement of blood urea nitrogen (BUN)/serum creatinine, prior to the initial infusion of Octagam 10% and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of the product. 5.3 Blood Glucose Monitoring Some glucose monitoring systems give falsely elevated glucose readings because they interpret the maltose in Octagam 10% as glucose.[ 2 ] This occurs in systems that use glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ) or glucose-dye-oxidoreductase methods for detecting blood glucose. Inaccurate glucose readings can cause inappropriate administration of insulin and resultant potentially life-threatening hypoglycemia. Also, true hypoglycemia may go undetected when masked by a falsely elevated glucose reading. Monitor glucose levels in diabetic patients with a glucose-specific method only. Review the product information of blood glucose testing systems, including the test strips, to determine if the system is appropriate to use with maltose-containing parenteral products. Contact the manufacturer if there is any uncertainty about the system. 5.4 Hyperproteinemia, Increased Serum Viscosity and Hyponatremia Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving Octagam 10% therapy. It is clinically critical to distinguish true hyponatremia from pseudohyponatremia related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity and a higher risk of thromboembolic events.[ 3 ] 5.5 Thrombosis Thrombosis may occur following treatment with immune globulin products, including Octagam 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia / markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombotic events, administer Octagam 10% at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [ 4-6 ] (See BOXED WARNING, DOSAGE and ADMINSTRATION [ 2.3 ], PATIENT COUNSELING INFORMATION [ 17 ]) 5.6 Hemolysis Octagam 10% may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin test (DAT) (Coombs’ test) result and hemolysis. Delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration and acute hemolysis, consistent with intravascular hemolysis, has been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. The following risk factors may be associated with the development of hemolysis following IGIV administration: high doses (e.g. ≥ 2 g/kg), given either as a single administration or divided over several days, and non-O blood group.[ 7 ]. Other individual patient factors, such as an underlying inflammatory state (as may be reflected by, for example, elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV.[ 8 ], but their role is uncertain. Hemolysis has been reported following administration of IGIV for a variety of indications, including ITP. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis. 5.7 Aseptic Meningitis Syndrome Aseptic meningitis syndrome (AMS) may occur with Octagam treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following rapid infusion with Octagam treatment. It is characterized by symptoms and signs including severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl, but negative culture results. Conduct a thorough neurological examination in patients exhibiting such symptoms and signs, including CSF studies, to rule out other causes of meningitis. It appears that patients with a history of migraine may be more susceptible.[ 9 ] AMS may occur more frequently following high doses (≥2 g/kg) and/or rapid infusion of IGIV. 5.8 Transfusion-Related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)] may occur in patients administered IGIV.[ 10 ] TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Signs and symptoms typically appear within 1 to 6 hours after transfusion. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support. Monitor recipients of Octagam 10% for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-HLA and anti-neutrophil antibodies in the product. 5.9 Transmission of Infectious Agents Because Octagam 10% is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Report all infections thought by a physician or other healthcare provider to have been possibly transmitted by this product to Pfizer Inc. at 1-800-438-1985. Discuss the risks and benefits of Octagam 10% with the patient before prescribing or administering this product. 5.10 Monitoring Laboratory Tests After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g. A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test. Clinically assess patients with known renal dysfunction, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or those receiving nephrotic agents, and monitor as appropriate (BUN; serum creatinine, urine output) during therapy with Octagam 10%. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with polycythemia, cryoglobulins, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies. Consider measuring hemoglobin or hematocrit at baseline and approximately 36 to 96 hours post infusion in patients at higher risk of hemolysis. If signs and/or symptoms of hemolysis are present after an infusion of Octagam 10%, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Chronic Immune Thrombocytopenic Purpura (ITP) The most common adverse reactions observed in > 5% of clinical study subjects with ITP were headache, fever, and increased heart rate. Dermatomyositis (DM) The most common adverse reactions observed in > 5% of clinical study subjects with DM were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusions site reactions. Chronic ITP: The most common adverse reactions reported in greater than 5% of subjects during a clinical trial were headache, fever and increased heart rate ( 6 ). Dermatomyositis: The most common adverse reactions reported in greater than 5% of subjects during a clinical trial were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusions site reactions (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice. Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) in Adults In a prospective, open-label, single-arm, multicenter study 116 subjects with newly diagnosed or chronic ITP received Octagam 10% at a dose of 2 g/kg, administered daily as 1 g/kg intravenous infusions on 2 consecutive days. In the initial study phase, the infusion rate allowed for Octagam 10% administration was up to 6 mg/kg/min [0.06 mL/kg/min], which was achieved in 24 of 26 subjects (92%). Subsequently, the maximum infusion rate allowed was 12 mg/kg/min [0.12mL/kg/min], and 54 (60%) of 90 subjects received Octagam 10% at this rate in the second phase of the trial. Pre-medication to alleviate potential adverse drug reactions was allowed, and was only administered to 1 (0.9%) of the 116 patients. The investigators judged 129 (54%) of the temporally associated ("infusional") adverse reactions (AR) in 62 patients to be at least possibly related to the infusion of Octagam 10%. The most common causally related ARs observed in > 5% of subjects are shown in Table 2. Table 2: Drug-related Adverse Reactions Experienced by >5% of Subjects Reactions No. of Subjects (% of Subjects [n=116]) Headache 29 (25) Pyrexia 17 (15) Heart Rate Increased 13 (11) Table 3: ARs in >5% Subjects During and Within 72 Hours After the End of 2-Days Treatment Cycle, Irrespective of Causality Reactions No. of Subjects (% of Subjects [n=116]) Headache 35 (30) Heart Rate Increased 25 (22) Pyrexia 20 (17) Heart Rate Decreased 18 (16) Hypertension 7 (6) One subject experienced a serious adverse reaction (headache). Treatment of Dermatomyositis (DM) in Adults In a prospective, double-blind, randomized, placebo-controlled, multicenter study with two study periods, 95 adults with DM were enrolled. In the First Period (16 weeks), 47 subjects received 2 g/kg Octagam 10% and 48 subjects received placebo every 4 weeks for 4 infusion cycles. In the following 6-month open-label Extension Period, 91 subjects received 6 infusion cycles of Octagam 10% (one infusion cycle every 4 weeks). One infusion cycle comprised of all infusions administered over 2-5 days. Table 4 and Table 5 summarize the most frequent adverse reactions (ARs) that occurred in >5% of subjects with DM in the clinical study. Premedication for infusions was given to 21.3% of patients in the Octagam group. During the study, no subject met the criteria for a hemolytic transfusion reaction (HTR). No deaths were reported during the study. The following serious adverse reactions were observed in the study: muscle spasms and dyspnea in one subject, loss of consciousness in one subject, and thromboembolic events (TEEs) in five subjects, including deep vein thrombosis and pulmonary embolism in one subject, cerebrovascular accident in one subject, cerebral infarction in one subject, hypoesthesia in one subject and pulmonary embolism in one subject. For risk factors for TEE see also [ 5.5 ]). Table 4: Drug-related Adverse Reactions Experienced by >5% of Subjects Reactions No. of Subjects (% of Subjects [n=95]) Headache 40 (42) Pyrexia 18 (19) Nausea 15 (16) Vomiting 8 (8) Chills 7 (7) Musculoskeletal pain 7 (7) Blood pressure increased 6 (6) Table 5: ARs in >5% of Subjects During and Within 72 Hours After End of Infusion Cycle, Irrespective of Causality Reactions No. of Subjects (% of Subjects [n=95]) Headache 44 (46) Pyrexia 19 (20) Nausea 16 (17) Vomiting 8 (8) Blood pressure increased 8 (8) Chills 7 (7) Musculoskeletal pain 5 (5) Heart Rate Increased 5 (5) Dyspnea 5 (5) Infusion site reactions 5 (5) 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. The following adverse reactions have been identified during post-approval use of Octagam. Blood and lymphatic system disorders Leucopenia, hemolytic anemia Immune system disorders Hypersensitivity, anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, angioedema, face edema Metabolic and nutritional disorders Fluid overload, (pseudo)hyponatremia Psychiatric disorders Agitation, confusional state, anxiety, nervousness Nervous system disorders Cerebrovascular accident, loss of consciousness, speech disorder, aseptic meningitis, migraine, dizziness, paresthesia, hypoesthesia, tremor, photophobia, Eye disorders Visual impairment Cardiac disorders Myocardial infarction, angina pectoris, bradycardia, tachycardia, palpitations, cyanosis Vascular disorders Hypotension, thrombosis, circulatory collapse, peripheral circulatory failure, hypertension, phlebitis, pallor Respiratory, thoracic and mediastinal disorders Respiratory failure, pulmonary embolism, pulmonary edema, bronchospasm, dyspnea, cough, hypoxia Gastrointestinal disorders Nausea, vomiting, diarrhea, abdominal pain Skin and subcutaneous tissue disorders Eczema, skin exfoliation, urticaria, rash, rash erythematous, dermatitis, erythema, pruritus, alopecia Musculoskeletal and connective tissue disorders Back pain, arthralgia, myalgia, pain in extremity, neck pain, muscle spasms, muscular weakness, musculoskeletal stiffness Renal and urinary disorders Acute renal failure, renal pain General disorders and administration site conditions Fatigue, oedema, injection site reaction, pyrexia, influenza-like illness, chills, chest pain, chest discomfort, hot flush, flushing, feeling hot, feeling cold, hyperhidrosis, malaise, lethargy, asthenia, burning sensation Investigations Hepatic enzymes increased, falsely elevated blood glucose level Injury, poisoning and procedural complications Transfusion-related acute lung injury
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Reactions</content></td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> No. of Subjects (% of Subjects [n=116])</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 29 (25)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Pyrexia</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 17 (15)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Heart Rate Increased</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 13 (11)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Reactions</content></td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> No. of Subjects (% of Subjects [n=116])</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 35 (30)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Heart Rate Increased</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 25 (22)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Pyrexia</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 20 (17)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Heart Rate Decreased</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 18 (16)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Hypertension</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 7 (6)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Reactions</content></td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> No. of Subjects (% of Subjects [n=95])</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 40 (42)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Pyrexia</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 18 (19)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Nausea</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 15 (16)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Vomiting</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 8 (8)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Chills</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 7 (7)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Musculoskeletal pain</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 7 (7)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Blood pressure increased</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 6 (6)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.